skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Dronedarone in the management of atrial fibrillation

Review

(2365) Views  (1021) Full article downloads

Authors: TS Mohamed Saleem, K Bharani, C Madhusudhana Chetty, et al

Published Date March 2010 Volume 2010:2 Pages 17 - 23
DOI: http://dx.doi.org/10.2147/OAEM.S8988

TS Mohamed Saleem1, K Bharani, C Madhusudhana Chetty, K Gauthaman2

1Department of Pharmacology, Annamacharya College of Pharmacy, New Boyanapalli, Rajampet, Andhrapradesh, India; 2Department of Pharmacognosy, Himalayan Pharmacy Institute, Majhitar, Sikkim, India

Abstract: Atrial fibrillation is the most common type of tachyarrhythmia caused by multiple re-entrant wave forms within the atria and bombarding the atrioventricular node several times making it beat in a rapid, disorganized fashion termed “fibrillation”. In atrial fibrillation, atria beat more than 300 times per minute. The arrhythmatous condition needs to be controlled, as humans cannot withstand this rapid and chaotic beating of the heart. New investigational drugs like Dronedarone® are being used. Dronedarone is the most recent antiarrhythmic drugs. It was approved by US-FDA on July 2nd 2009 and is available in the USA as Multaq tablets (400 mg). Dronedarone falls under the category of multiple ion channel blocker. It mainly targets the repolarization currents, making them less active and hence prolonging the action potential duration (APD). Dronedarone also exhibits antiadrenergic activity, thus reducing the pace of the pacemaker. Dronedarone has been proven to be a safer and efficacious AAD, evidenced by both animal and human studies. These studies showed that there was prolongation of the APD and absence of QT interval prolongation with long term administration of the drug. Also there was reduced thyroid hormone receptor expression. Dronedarone is significantly safer and effective in maintaining the sinus rhythm and reducing the ventricular proarrhythmias, justifying it for the long term treatment of atrial fibrillation compared to other antiarrhythmic drugs.

Keywords: dronedarone, atrial fibrillation, ion channel blocker, antiarrhythmic drugs, multaq






 

Other articles by Mr TSM Saleem



Readers of this article also read:

Problems and barriers of pain management in the emergency department: Are we ever going to get better?
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Focused versus screening CT scans for evaluation of nontraumatic abdominal pain in the emergency department
ACE inhibitors – angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease
Antimicrobial prophylaxis in open lower extremity fractures
Emerging treatment options for spasticity in multiple sclerosis – clinical utility of cannabinoids
Erratum
A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose
Update on pediatric dystonias: etiology, epidemiology, and management